motexafin-gadolinium has been researched along with Graft-Occlusion--Vascular* in 1 studies
1 other study(ies) available for motexafin-gadolinium and Graft-Occlusion--Vascular
Article | Year |
---|---|
Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model.
Motexafin lutetium (Lu-Tex) is a photosensitizer that targets atheromatous plaque. Subsequent photoactivation (photodynamic therapy [PDT]) induces local cytotoxic effects. The aim of the present study was to investigate whether Lu-Tex targets vein graft intimal hyperplasia and whether subsequent photoactivation attenuates the disease process.. The subcellular localization of Lu-Tex and postillumination viability were studied in cultured human vein graft smooth muscle cells. Inferior vena cava-grafted rats were injected with Lu-Tex (10 mg/kg) 4 or 12 weeks after grafting. Biodistribution was assessed in a subgroup 24 hours after administration. Light therapy (742 nm) was performed 24 hours after Lu-Tex injection by illuminating intraperitoneally placed isografts using a laparotomy. Animals were divided into the following 4 groups: PDT (n=15), Lu-Tex injection and laparotomy (n=13), light treatment (n=14), and laparotomy only (n=13). Grafts were harvested 14 days after treatment for histochemical analysis. Lu-Tex localized within subcellular organelles of smooth muscle cells, and subsequent photoactivation induced cell death via apoptosis. The Lu-Tex concentrations present in the vein grafts were 9.3 times higher than those in the normal inferior vena cava. Postoperative PDT at 4 weeks after surgery significantly reduced the intima/media ratio, whereas treatment at 12 weeks did not reduce the intima/media ratio. Activated macrophages were observed 4 weeks after grafting; however, a significant reduction occurred in these cells by 12 weeks. The mechanism by which PDT works may be related to the presence of activated macrophages.. PDT significantly reduces the intima/media ratio in the early phase of vein graft disease. Lu-Tex-mediated PDT may be a viable method for the attenuation of atherosclerotic disease in vein grafts. Topics: Animals; Antigens, Differentiation; Cells, Cultured; Graft Occlusion, Vascular; Humans; Hyperplasia; Laparotomy; Light; Macrophages; Metalloporphyrins; Muscle, Smooth, Vascular; Photochemotherapy; Photosensitizing Agents; Rats; Tissue Distribution; Transplantation, Isogeneic; Tunica Intima; Vena Cava, Inferior | 2000 |